TD Cowen: 'TRDA is poised to enter several potential inflection points this year'
Tweet Send to a Friend
TD Cowen analyst Joseph Thome reiterated a Buy rating and {REMOVEPT} price target on Entrada Therapeutics (NASDAQ: TRDA)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
